Global Infectious Disease Drugs Market Analysis

Global Infectious Disease Drug Market Executive Summary

The Infectious Disease Drug market has been significantly impacted by the COVID-19 epidemic. Healthcare facilities are experiencing shortages and unavailability of infectious drugs and supplies as a result of the market impact of employment closures curtailing import and export activities. The initial phase of the outbreak had a significant influence on the market for infectious pharmaceuticals due to the temporary shutdown of production facilities, export restrictions, increased demand for COVID-19 medication, disruptions in the supply of goods, and interruptions in services. Additionally, fewer clinical trials of the medication have been conducted as more businesses postpone the beginning of the majority of new courses in a number of nations.

Market Size and Key Findings

The Global Infectious Disease Drug Market size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.

Global Infectious Disease Drug Market Size (In $Bn)

(2021-2030F)

Market Dynamics

Market Growth Drivers & Restraints Analysis

Over the forecast period, the main driver driving the demand for infectious illness medications would be the increasing prevalence of malaria diseases. For instance, based on data from the World Health Organization (WHO) released in 2021, Sub-Saharan Africa is anticipated to continue to bear the brunt of malaria, which is responsible for 96% of all deaths and roughly 95% of all cases. Additionally, according to the WHO study "World Malaria Report" issued in 2021, 96% of all malaria cases in 2020 were found in 29 of the 85 countries where the disease is endemic. Around 1.7% of malaria cases and 1.2% of malaria fatalities worldwide originated in India. The same source estimates that there were 227 million cases of malaria in 2019, but 241 million cases in 2020. Thus, the rising incidence of malaria cases globally is projected to increase the need for anti-malarial medications, which in turn raises the demand for infectious diseases and spurs market expansion.

Competitive Landscape

Key Players

Due to the existence of several market participants, the industry under study is fragmented. AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., F Hoffmann-La Roche, Ltd, Boehringer Ingelheim GmbH, Janssen Pharmaceutical (Johnson & Johnson), and Novartis AG are a few of the major participants.